IXOREAL BIOMED INC. – Trademark Portfolio

Entity Type: 03

IXOREAL BIOMED INC. holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 2 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 2 trademarks are registered and 2 are pending. Notable registered marks include KSM-66 and KSM-66 ASHWAGANDHA. The owner is based in Los Angeles, CA.

1039 Selby Avenue

Los Angeles, CA 90024-3105

4 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

IXOREAL BIOMED INC.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

1
Chemicals (2 filings)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

5
Pharmaceuticals (2 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does IXOREAL BIOMED INC. have?

IXOREAL BIOMED INC. has 4 U.S. trademarks filed with the USPTO. Of these, 2 registered, 2 pending.

What trademark classes does IXOREAL BIOMED INC. file in?

IXOREAL BIOMED INC. files trademarks across 2 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 5 (Pharmaceuticals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.

What are IXOREAL BIOMED INC.'s most well-known trademarks?

IXOREAL BIOMED INC.'s registered trademark portfolio includes well-known marks such as KSM-66 and KSM-66 ASHWAGANDHA. These are among 2 currently registered trademarks in the portfolio.

What is IXOREAL BIOMED INC.'s trademark registration success rate?

IXOREAL BIOMED INC. has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 2 applications are pending review.